Administration Time-dependent Antihypertensive Effects of Low Dose Aspirin in Well-controlled Hypertensive Patients
NCT ID: NCT00386529
Last Updated: 2010-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
191 participants
INTERVENTIONAL
2006-09-30
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Approximately 192 patients will be enrolled over 4 months in 8 centers nationwide.
After placebo run-in period, all subjects will be randomized into one of the following 3 groups.
Group I \& II will take low dose aspirin for treatment period (for first and second 12 weeks)on awakening or before bed time. Group III will take placebo for treatment period.
After first 12 weeks' treatment period, the subjects will be informed whether she/he belongs to Group III. This will be done without breaking the double blinding in the other 2 groups.
The primary objective will be the evaluation of the influence of aspirin on blood pressure in well-controlled hypertensive patients who receive low dose aspirin at different times of the day.
The secondary objectives will be 1) comparison of the administration time-dependent effects of low dose aspirin on blood pressure between dipper and non-dipper patients and 2) the evaluation of the effects of low dose aspirin in Korean hypertensive patients.
A sub-study will be conducted in 3 centers to evaluate the effect of aspirin on endothelial function in patients with well-controlled hypertension.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aspirin enteric coated pellests 100mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Essential hypertension without complication
* Well-controlled blood pressure over 3 months with same antihypertensive medication without changes in dose and frequency
* Averages of two consecutive sitting diastolic and systolic blood pressures are \<90 mmHg and \<140 mmHg, respectively at screening and visit 1
* Differences in sitting diastolic and systolic blood pressures between screening and visit 1 are 10 mmHg and 20 mmHg, respectively.
* Willing and able to give informed consent
Exclusion Criteria
* patients with secondary or malignant hypertension
* patients with complication or high risk of complication
* proven coronary artery or peripheral vascular diseases
* Framingham CHD Risk Score (10 years) 20
* Fasting blood glucose 110 mg/dl
* Hyperlipidemia under treatment or treatment required
* patients with myocardial infarction or severe cerebrovascular disorder in last 6 months
* patients with chronic renal insufficiency
* patients with unstable angina
* patients with severe left ventricular abnormalities or valvular defect
* patients with bradycardia(pulse rate \< 50 times/min) or chronic tachycardia (pulse rate 100 times/min), second degree AV-block
* SGOT, SGPT\> 2.5 times upper limit range or serum creatinine \> 1.5 times upper limit range
* patients with unresolved malignant tumor or systemic infection
* lactating or pregnant females or females of childbearing potential who do not undergo hysterectomy or are not willing to use "effective" method of contraception.
* known hypersensitivities to the investigational drug
* patients judged to have alcohol or other drug abuse by the investigator
* patients who takes contraindicated drug at study entry (visit 1) or needs to contraindicated drug throughout the study period(if judged by the investigator not to influence on the study due to the temporal administration etc.)
* patients judged to be inappropriate for this study be the investigator
* patients with gastrointestinal troubles to NSAIDs
30 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kyungpook National University Hospital
OTHER
The Catholic University of Korea
OTHER
Cheil General Hospital and Women's Healthcare Center
OTHER
Inje University
OTHER
Keimyung University
OTHER
Seoul National University Bundang Hospital
OTHER
Severance Hospital
OTHER
Yeungnam University Hospital
OTHER
Boryung Pharmaceutical Co., Ltd
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shung Chull Chae, Professor
Role: STUDY_CHAIR
Kyungpook National University Hospital
Dong Ju Choi, Professor
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Bundang Hospital
Dong Su Kim, Professor
Role: PRINCIPAL_INVESTIGATOR
Inje University
Jeong Bae Park, Professor
Role: PRINCIPAL_INVESTIGATOR
Cheil General Hospital and Women's Healthcare Center
Nam Sik Chung, Professor
Role: PRINCIPAL_INVESTIGATOR
Severance Hospital
Sang Hong Baek, Professor
Role: PRINCIPAL_INVESTIGATOR
The Catholic University of Korea
Chang Wook Nam, Professor
Role: PRINCIPAL_INVESTIGATOR
Keimyung University Dongsan Medical Center
Young Jo Kim, Professor
Role: PRINCIPAL_INVESTIGATOR
Yeungnam University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kyungpook National University Hospital
Daegu, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Avanzini F, Palumbo G, Alli C, Roncaglioni MC, Ronchi E, Cristofari M, Capra A, Rossi S, Nosotti L, Costantini C, Pietrofeso R. Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. Collaborative Group of the Primary Prevention Project (PPP)--Hypertension study. Am J Hypertens. 2000 Jun;13(6 Pt 1):611-6. doi: 10.1016/s0895-7061(00)00231-4.
Magen E, Viskoper JR, Mishal J, Priluk R, London D, Yosefy C. Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. J Hum Hypertens. 2005 Sep;19(9):667-73. doi: 10.1038/sj.jhh.1001910.
Hermida RC, Fernandez JR, Ayala DE, Mojon A, Iglesias M. Influence of aspirin usage on blood pressure: dose and administration-time dependencies. Chronobiol Int. 1997 Nov;14(6):619-37. doi: 10.3109/07420529709001452.
Hermida RC, Ayala DE, Iglesias M. Administration time-dependent influence of aspirin on blood pressure in pregnant women. Hypertension. 2003 Mar;41(3 Pt 2):651-6. doi: 10.1161/01.HYP.0000047876.63997.EE. Epub 2002 Dec 9.
Hypertension 2005;46[part2]:1060-1068
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AST-HT-01
Identifier Type: -
Identifier Source: org_study_id